Bullous Keratopathy, Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Endothelial Dysfunction, Fuchs Dystrophy, Fuchs Endothelial Corneal Dystrophy, Moderate Corneal Endothelial Decompensation, Pseudophakic Bullous Keratopathy
Conditions
Brief summary
Corneal edema is the most common indication for corneal transplantation, accounting for approximately 70% of penetrating keratoplasty (PK), and 100% of endothelial keratoplasty (EK) procedures annually. There is currently no disease-modifying treatment for corneal edema. Topical treatments like hypertonic saline are not effective on a long-term basis. For those with advanced disease, where edema and vision loss are not controlled by topical treatment, the only option is a corneal transplant. A potential approach to avoidance of the risks of corneal transplantation is to inject cultured human corneal endothelial cells (HCECs) into the anterior chamber of the eye. This approach may avoid surgery by re-populating the inner most aspect of the cornea with functioning endothelial cells. Emmecell has developed a treatment based on technology integrating biocompatible magnetic nanoparticles with cultured HCECs to treat corneal edema in a minimally invasive way. The primary objective of this phase 1, prospective, multi-center, open-label, dose-escalation study is to evaluate the safety and tolerability of 3 doses of EO2002 with and without endothelial brushing (EB) or Descemet Stripping (DS) in eyes with corneal edema secondary to corneal endothelial dysfunction that qualify for surgery involving full-thickness corneal transplantation or EK.
Detailed description
The study is designed to occur in 2 groups. The objective with the first group is to preliminarily evaluate the safety of 4 escalating doses. The purpose of the second group is to gather additional safety information on the 3 highest doses when administered according to a randomized schedule and evaluated by masked observers. Group 1: Phase 1 prospective, multi-center, open-label, dose-escalation study designed to evaluate the safety and tolerability of EO2002 with and without endothelial brushing (EB) or Descemet Stripping (DS) in eyes with corneal edema secondary to corneal endothelial dysfunction that qualify for surgery involving full-thickness corneal transplantation or EK. Four doses will be studied in approximately 21 study participants that meet the inclusion/exclusion criteria. Safety and tolerability will be the primary focus for 26 weeks following treatment with EO2002. Group 2: The three highest doses will be administered to up to 21 subjects in a randomized, double-masked design.
Interventions
BIOLOGICALEO2002
EO2002 (magnetic human corneal endothelial cells \[HCECs\]) with and without endothelial brushing (EB) or Descemet Stripping (DS)
BIOLOGICALEO2002 low dose
Low dose of EO2002 (magnetic human corneal endothelial cells)
BIOLOGICALEO2002 mid dose
Mid dose of EO2002 (magnetic human corneal endothelial cells)
BIOLOGICALEO2002 high dose
High dose of EO2002 (magnetic human corneal endothelial cells)
Sponsors
Emmecell
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Group 1: Open-Label, Dose-Escalation Study Group 2: Randomized, double masked
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
All ocular criteria apply to study eye unless otherwise noted. 1. Age ≥ 21 years. 2. Phakic or Pseudophakic with a posterior chamber intraocular lens 3. Symptomatic corneal edema associated with endothelial dysfunction which may be secondary to Fuchs corneal dystrophy or pseudophakic bullous keratopathy.
Exclusion criteria
All ocular criteria apply to study eye unless otherwise noted. 1. Other corneal disease 2. Anterior chamber intraocular lens, Sutured or scleral-fixated intraocular lens. 3. Macular disease that in the investigator and/or sponsor's opinion would limit the ability of the subject to demonstrate improvement in BCVA. 4. History of refractive surgery. 5. Descemet membrane detachment. 6. History of uveitis or other ocular inflammatory disease. 7. History of incisional glaucoma surgery (e.g.,trabeculectomy, glaucoma drainage implant). 8. Intraocular pressure \>21 or \<7 mm Hg 9. Prior incisional eye surgery within 3 months prior to study treatment or penetrating or endothelial keratoplasty. 10. History of ocular neoplasm. 11. ETDRS BCVA in the fellow eye is worse than 35 letters (Snellen equivalent of 20/200). 12. Female who is pregnant, nursing, or planning to become pregnant, or who is of childbearing potential and not using a reliable means of contraception during the study. 13. Subject is currently participating in or has participated within the last 3 months in any other clinical trial of an investigational drug by ocular or systemic administration. 14. Any concomitant medical or psychological condition that could interfere with study participation or is otherwise not suitable for entry into the study in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability of EO2002] | 26 Weeks | Incidence of Treatment-Emergent Adverse Events \[Safety and Tolerability of EO2002 (+/- EB or Descemet Stripping)\] in subjects with corneal edema at week 26. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effect of EO2002 (+/-EB or DS) on corneal thickness | 26 Weeks | Evaluate the effect of a single injection of EO2002 (+/-EB or DS) on corneal thickness as determined by pachymetry |
| Effect of EO2002 (+/-EB or DS) on best corrected visual acuity (BCVA). | 26 Weeks | Evaluate the effect of a single injection of EO2002 (+/-EB or DS) on best corrected visual acuity (BCVA) as determined by ETDRS letter score. |
Countries
United States
Outcome results
None listed